280. Huge arteriovenous malformation with cervicofacial or limb lesion Clinical trials / Disease details
Clinical trials : 25 / Drugs : 29 - (DrugBank : 15) / Drug target genes : 14 - Drug target pathways : 153
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05125471 (ClinicalTrials.gov) | January 2022 | 12/11/2021 | COBI-AVM Study - Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib In Extracranial Arteriovenous Malformations (AVM) | COBI-AVM Study - Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib In Extracranial Arteriovenous Malformations (AVM) | Arteriovenous Malformations (Extracranial) | Drug: Cobimetinib | University of Arkansas | Genentech, Inc. | Not yet recruiting | 2 Years | 80 Years | All | 17 | Phase 2 | NULL |